Point-of-care biomarker assay for traumatic brain injury

New Rochelle, NY, September 16, 2020







—Intracranial abnormalities on CT scan in patients with traumatic brain injury (TBI) can be predicted by glial fibrillary acidic protein (GFAP) levels in the blood. These interim findings from the TRACK-TBI study are published in the peer-reviewed


Journal of Neurotrauma


.


Click here


to read the article now.

GFAP’s diagnostic performance was significantly better than that of the S100B biomarker, to which it was compared. S100B is approved for use in Europe, but not in the U.S.

“GFAP substantially outperformed S100B as a TBI diagnostic biomarker of positive head CT scans,” state


David Okonkwo, MD, PhD


, University of Pittsburgh Medical Center,


Amy Markowitz, JD


, University of California, San Francisco, and coauthors.

“Our results validate a point-of-care platform prototype GFAP assay that delivers results in minutes (<15 min) versus hours for the current FDA-cleared assay,” state the authors.

“This is a particularly important study with major implications for the diagnosis and prognoses of traumatic brain injury. The large sample size and the rigorous inclusion criteria increase the impact of the reported study, which strongly reaffirms the utility of GFAP as a diagnostic marker for CT-detected lesions. It also demonstrates the utility of a point-of-care approach. As noted by the authors, the reported studies demonstrate GFAP’s utility across the spectrum of TBI, evaluated over a relatively prolonged posttraumatic time course,” says


John Povlishock, PhD


, Editor-in-Chief of



Journal of Neurotrauma



.

About the Journal














Journal of Neurotrauma






is an authoritative peer-reviewed journal published 24 times per year in print and online that focuses on the latest advances in the clinical and laboratory investigation of traumatic brain and spinal cord injury. Emphasis is on the basic pathobiology of injury to the nervous system, and the papers and reviews evaluate preclinical and clinical trials targeted at improving the early management and long-term care and recovery of patients with traumatic brain injury.


Journal of Neurotrauma


is the official journal of the


National Neurotrauma Society


and the International Neurotrauma Society. Complete tables of content and a sample issue may be viewed on the






Journal of Neurotrauma






website.

About the Publisher





Mary Ann Liebert, Inc., publishers


is known for establishing authoritative peer-reviewed journals in promising areas of science and biomedical research. A complete list of the firm’s 90 journals, books, and newsmagazines is available on the


Mary Ann Liebert, Inc., publishers


website.